- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about INCY
Recent news which mentions INCY
Incyte's Topical JAK Inhibitor Under Priority FDA Review For Depigmented Skin Disorder
December 15, 2021
Tickers
INCY
From Benzinga
Watch These 12 Nasdaq Stocks in 2022
December 13, 2021
From Motley Fool
Lucid and Rivian Are Soaring Again. Which EV Stock Is The Better Buy?
December 13, 2021
From Motley Fool
From Benzinga
7 CEOs That Ought to Follow Jack Dorsey Out the Door
December 10, 2021
From InvestorPlace
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
From Benzinga
7 Stocks 'On Sale' This Holiday Season
November 26, 2021
From Benzinga
Is This Pharma Stock a Buy?
November 22, 2021
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
November 19, 2021
From Benzinga
From Benzinga
These Clinical Results Are Good News for AstraZeneca
November 06, 2021
From Motley Fool
Incyte Corporation (INCY) Q3 2021 Earnings Call Transcript
November 02, 2021
Tickers
INCY
From Motley Fool
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
November 02, 2021
From Benzinga
From Benzinga
Incyte's Parsaclisib Application Under FDA Review For 3 Types Of Non-Hodgkin Lymphomas
November 01, 2021
Tickers
INCY
From Benzinga
Put these 10 stocks on your radar because they may rebound from recent tax-loss selling
November 01, 2021
From MarketWatch
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
From Benzinga
2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays
October 27, 2021
From Motley Fool
Could This Be the Next Blockbuster Indication for Eli Lilly?
October 21, 2021
From Motley Fool
From Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
October 06, 2021
From Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
October 05, 2021
From Benzinga
From Benzinga
More than a quarter of Nasdaq-100 stocks are in bear markets — Wall Street sees a buying opportunity
September 29, 2021
From MarketWatch
Only 47 stocks in the S&P 500 have fallen over the past year — Wall Street predicts they will climb up to 54% in 12 months
September 28, 2021
From MarketWatch
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
September 28, 2021
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.